<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60388">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01896635</url>
  </required_header>
  <id_info>
    <org_study_id>FOCUS</org_study_id>
    <nct_id>NCT01896635</nct_id>
  </id_info>
  <brief_title>Faecal Microbiota Transplantation in Ulcerative Colitis</brief_title>
  <acronym>FOCUS</acronym>
  <official_title>Faecal Microbiota Transplantation for Chronic Active Ulcerative Colitis - A Randomised Double Blind Controlled Study of Efficacy &amp; Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of New South Wales</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of New South Wales</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Australia: Human Research Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether fecal microbiota transplantation (FMT) is
      safe and efficacious in the treatment and induction of remission of chronic active
      ulcerative colitis (UC) by conducting a randomised controlled trial
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical remission as measured by Mayo subscores</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical and Endoscopic remission as measured by Mayo subscores and UCEIS</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response as measured by Mayo subscores</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic healing as measured by UCEIS</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure rate as defined by Mayo subscores</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by IBDQ</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as measured by adverse event data</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Ulcerative Colitis</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>FMT infusions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FMT infusions constituted from stool provided by healthy, screened donors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo infusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FMT infusions</intervention_name>
    <arm_group_label>FMT infusions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo infusion</intervention_name>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ulcerative colitis &gt;3 months duration

          -  Active mild-moderate ulcerative colitis (Mayo 4-10)

          -  Ulcerative colitis of any extent except isolated proctitis &lt; 5cm

          -  Live within driving distance of clinical site (to attend multiple study visits)

        Exclusion Criteria:

          -  Pregnancy

          -  Active gastrointestinal infection

          -  Other gastrointestinal disease / comorbidities

          -  Prior colonic surgery

          -  Recent antibiotic or probiotic use

          -  Prednisone &gt; 20mg

          -  Monoclonal antibody immunosuppressive therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hazel Mitchell, BSc(Hons), Dip Ed, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New South Wales</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alissa Walsh, MBBS (Hons) FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Vincent's Hospital, Sydney</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johan van den Bogaerde, MBChB PhD FCP MMed FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nambour General Hospital, Queensland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Douglas Samuel, BSc(Med) MBBS(Hons) MMed FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bankstown-Lidcombe Hospital, Sydney</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nadeem O Kaakoush, BSc(Hons), PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New South Wales</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Kamm, MBBS, MD, FRCP, FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Melbourne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sudarshan Paramsothy, BSc(Med)MBBS MRCP FRACP</last_name>
    <phone>(61 2) 8382 2061</phone>
    <email>sparam_au@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alissa Walsh, MBBS (Hons) FRACP</last_name>
    </contact>
    <investigator>
      <last_name>Alissa Walsh, MBBS (Hons) FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bankstown-Lidcombe Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2200</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Samuel, BSc(Med) MBBS(Hons) MMed FRACP</last_name>
    </contact>
    <investigator>
      <last_name>Douglas Samuel, BSc(Med) MBBS(Hons) MMed FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nambour General Hospital</name>
      <address>
        <city>Nambour</city>
        <state>Queensland</state>
        <zip>4560</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan van den Bogaerde, MBChB, MMed, PhD, MRCP, FRACP</last_name>
    </contact>
    <investigator>
      <last_name>Johan van den Bogaerde, MBChB, MMed, PhD, MRCP, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 23, 2014</lastchanged_date>
  <firstreceived_date>July 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of New South Wales</investigator_affiliation>
    <investigator_full_name>Dr. Sudarshan Paramsothy</investigator_full_name>
    <investigator_title>Gastroenterologist / PhD candidate</investigator_title>
  </responsible_party>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>Fecal Transplantation</keyword>
  <keyword>Fecal Microbiota Transplantation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
